Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

334
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
334
Biopharmaceutics and Pharmacokinetics: Overview01:28

Biopharmaceutics and Pharmacokinetics: Overview

2.2K
Understanding drugs, drug products, and their performance in pharmaceutical science is pivotal. Drugs, whether simple molecules or complex compounds, are designed to interact with the body's biological systems to diagnose, treat, or prevent diseases. Drug products include various delivery systems such as tablets, capsules, injections, and inhalers. The performance of these drug products is gauged by their ability to deliver the active ingredient to the desired site of action at the...
2.2K
Human Genetics01:28

Human Genetics

657
Human genetics provides a profound framework for understanding the interplay between genetic predispositions and human psychology. At the heart of this discipline lies the study of how genes influence physical traits, behaviors, and susceptibility to diseases. Each person carries a unique genetic code that subtly or significantly shapes their psychological and behavioral landscape.
The complex relationship between genetics and psychology is observable through common biological components such...
657
Pharmacokinetic Models: Overview01:20

Pharmacokinetic Models: Overview

884
Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
884
Factors Affecting Drug Response: Overview01:21

Factors Affecting Drug Response: Overview

2.1K
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
2.1K
Pharmacovigilance01:19

Pharmacovigilance

940
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
940

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prevalence of CYP2C19 polymorphisms in medically and surgically managed patients with GERD.

Surgery·2026
Same author

Considerations for the clinical implementation of DPYD and UGT1A1-guided chemotherapy.

Pharmacogenomics·2026
Same author

Genetic variations in medical versus surgical patients with GERD: beyond PPIs and fundoplications.

Surgical endoscopy·2026
Same author

Prevalence of CYP2C19 phenotypes in patients undergoing a hiatal hernia repair.

Pharmacogenetics and genomics·2026
Same author

CYP2D6 phenotype and post-surgical pain control with hydrocodone and oxycodone.

Frontiers in pharmacology·2026
Same author

Distinguishing variability in hoarding symptom course across time.

BMC psychiatry·2026

Related Experiment Video

Updated: Aug 12, 2025

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

10.7K

Exploring perceptions, knowledge, and attitudes regarding pharmacogenetic testing in the medically underserved.

Brian E Gawronski1,2, Emily J Cicali1,2, Caitrin W McDonough1,2

  • 1Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Gainesville, FL, United States.

Frontiers in Genetics
|January 30, 2023
PubMed
Summary
This summary is machine-generated.

Medically underserved patients show strong interest in pharmacogenetic testing for personalized medication selection. Key concerns include cost and potential impact on insurance, highlighting needs for equitable implementation.

Keywords:
attitudesimplementationpharmacogeneticsurveyunderserved

More Related Videos

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
05:53

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

10.2K
An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
19:57

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

Published on: March 30, 2014

18.6K

Related Experiment Videos

Last Updated: Aug 12, 2025

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

10.7K
Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
05:53

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

10.2K
An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
19:57

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

Published on: March 30, 2014

18.6K

Area of Science:

  • Pharmacogenomics
  • Health Disparities
  • Clinical Implementation

Background:

  • Pharmacogenetic testing offers potential to reduce health disparities.
  • Medically underserved populations are prescribed guideline-based medications at higher rates.
  • Patient perspectives are crucial for successful clinical implementation.

Purpose of the Study:

  • To assess perceptions, knowledge, and attitudes towards pharmacogenetic testing among medically underserved patients.
  • To inform the equitable implementation of pharmacogenetic testing in diverse populations.

Main Methods:

  • A survey instrument was developed and refined through pilot testing.
  • The survey was administered nationwide to US adults with household incomes ≤$42,000.
  • Respondents included individuals without health insurance or on Medicaid.

Main Results:

  • Most respondents (78.9%) were unaware of pharmacogenetic testing prior to the survey.
  • A majority expressed interest in pharmacogenetic testing if free (60.5%) and supported its availability regardless of cost (75.8%).
  • Primary concerns included out-of-pocket costs (52.7%), potential disease risk disclosure, and insurance/care impact.

Conclusions:

  • Medically underserved populations demonstrate significant interest in pharmacogenetic testing.
  • Addressing concerns about cost, insurance, and perceived care improvement is vital for successful implementation.
  • Patient-centered approaches are essential for integrating pharmacogenetic testing equitably.